Treatment Options in Patients With R/R Multiple Myeloma in the Later-Line Setting

Target Switch and High-Risk Cohorts Support Talquetamab Use in RRMM

During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants reacted to data from the MonumenTAL-1 trial in the first article of a 2-part series.

Sequencing of Cell Therapies in Multiple Myeloma Continues Evolving

During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed how to implement use of bispecific T-cell engagers in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.

Lower-Intensity Talquetamab Dose Shows Potential in Multiple Myeloma

During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

Unanswered Questions on Sequencing Talquetamab for RRMM

During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, and participants discussed their impressions of the efficacy and safety of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.

Talquetamab Shows High Response Rates in BCMA-Pretreated RRMM

During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, discussed results of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.

Single-Agent Talquetamab Stands Out in Later-Line Treatment of RRMM

In the second article of a 2-part series, Amrita Krishnan, MD, looks at the overall landscape of treatment for patients with relapsed/refractory multiple myeloma and how the use of single-agent talquetamab stands out in comparison with other treatment options.

Talquetamab Shows Robust Response in R/R Multiple Myeloma

In the first article of a 2-part series, Amrita Krishnan, MD, discusses the two recent trials that show talquetamab’s promise for the treatment of patients with advanced multiple myeloma.